Art. -Nr.: HY-N0493

Pectolinarigenin

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Pectolinarigenin is an orally active dual inhibitor of COX-2/5-LOX with anti-inflammatory, antioxidant, antitumor and neuroprotective activities. Pectolinarigenin exerts neuroprotective and anti-inflammatory effects on astrocyte inflammation via the NFκB and MAPK pathways. Pectolinarigenin inhibits LPS-induced phosphorylation of ERK1/2, N-FκB and p38MAPK, directly inhibits the enzymatic activity or binding of COX-2, 5-LOX and HIF-1α, and reduces the level of XIAP. Pectolinarigenin modifies Keap1 to promote nuclear accumulation of Nrf2, induces ARE-mediated antioxidant enzyme expression, and possesses direct free radical scavenging activity. Pectolinarigenin reduces the release of NO, proinflammatory mediators and leukotrienes, and increases the level of IL-10. Pectolinarigenin induces G₂/M cell cycle arrest, apoptosis (Apoptosis) and autophagy (Autophagy) via the PI3K/AKT/mTOR signaling pathway. Pectolinarigenin reduces renal crystal deposition and inhibits melanin synthesis. Pectolinarigenin inhibits inflammation and alleviates allergy in mouse models of inflammation. Pectolinarigenin alleviates renal injury, inflammation and oxidative stress in mice by inhibiting HIF-1α activity. Pectolinarigenin can be used for the research of neurodegenerative diseases, inflammatory/allergic diseases, calcium oxalate nephrocalcinosis, gastric cancer, melasma, post-inflammatory diseases and chloasma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.98%
CAS. Nr.: 520-12-7
Formel: C₁₇H₁₄O₆
Molecular Weight:314.29

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Pectolinarigenin Chemical Structure

CAS. Nr.: 520-12-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Publications Citing Use of MedChemExpress (MCE) Pectolinarigenin

Customer Validation & Images

Histological Imaging/StainingIFWBCell Proliferation/Viability AssayApoptosis Analysis

Histological Imaging/Staining
IF
WB
Cell Proliferation/Viability Assay
Apoptosis Analysis

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

COX-2

5-LOX

Alle COX Isoform-spezifische Produkte anzeigen :

Alle Lipoxygenase Isoform-spezifische Produkte anzeigen :

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Alle p38 MAPK Isoform-spezifische Produkte anzeigen :

Alle ERK Isoform-spezifische Produkte anzeigen :

Alle HIF/HIF Prolyl-Hydroxylase Isoform-spezifische Produkte anzeigen :

Alle PI3K Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	8.2 μM Compound: 2	Antiproliferative activity against human A375 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human A375 cells after 48 hrs by sulforhodamine B assay	[PMID: 18818071]
A549	IC₅₀	5.6 μM Compound: 2	Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 18818071]
ACHN	IC₅₀	15.2 μM Compound: 2	Antiproliferative activity against human ACHN cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human ACHN cells after 48 hrs by sulforhodamine B assay	[PMID: 18818071]
ACHN	IC₅₀	15.23 μM Compound: Pectolinarigenin	In vitro inhibitory concentration against renal adenocarcinoma cell line (ACHN) in the presence of taxol In vitro inhibitory concentration against renal adenocarcinoma cell line (ACHN) in the presence of taxol	[PMID: 16125932]
C32	IC₅₀	7 μM Compound: 2	Antiproliferative activity against human C32 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human C32 cells after 48 hrs by sulforhodamine B assay	[PMID: 18818071]
Caco-2	IC₅₀	5.3 μM Compound: 2	Antiproliferative activity against human Caco-2 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human Caco-2 cells after 48 hrs by sulforhodamine B assay	[PMID: 18818071]
COR-L23	IC₅₀	4.07 μM Compound: Pectolinarigenin	In vitro inhibitory concentration against human carcinoma COR-L23 cells in the presence of vinblastine sulfate salt In vitro inhibitory concentration against human carcinoma COR-L23 cells in the presence of vinblastine sulfate salt	[PMID: 16125932]
COR-L23	IC₅₀	4.1 μM Compound: 2	Antiproliferative activity against human COR-L23 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human COR-L23 cells after 48 hrs by sulforhodamine B assay	[PMID: 18818071]
HepG2	IC₅₀	18.1 μM Compound: 2	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 30579802]
Jurkat	IC₅₀	>20 μM Compound: 2	Immunosuppressive activity in human Jurkat cells assessed as reduction in PHA + PMA-induced IL-2 production after 48 hrs by ELISA Immunosuppressive activity in human Jurkat cells assessed as reduction in PHA + PMA-induced IL-2 production after 48 hrs by ELISA	[PMID: 30579802]
KB	ED₅₀	3 μg/mL Compound: NSC-106403	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 469554]
L6	IC₅₀	20.2 μM Compound: 24	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue staining based fluorescence assay Cytotoxicity against rat L6 cells after 72 hrs by alamar blue staining based fluorescence assay	[PMID: 29244495]
MOLM-13	IC₅₀	5.9 μM Compound: 32	Cytotoxicity against human MOLM-13 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human MOLM-13 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33393294]
MRC5	IC₅₀	>159.2 μM Compound: Pectolinarigenin	In vitro inhibitory concentration against human fetal lung MRC-5 cell line in the presence of vinblastine sulfate salt In vitro inhibitory concentration against human fetal lung MRC-5 cell line in the presence of vinblastine sulfate salt	[PMID: 16125932]
MV4-11	IC₅₀	7.9 μM Compound: 32	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33393294]
NCI-H1975	IC₅₀	76.6 μM Compound: 2	Cytotoxicity against human NCI-H1975 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells after 72 hrs by MTT assay	[PMID: 30579802]
PC-9	IC₅₀	>80 μM Compound: 2	Cytotoxicity against human PC9 cells after 72 hrs by MTT assay Cytotoxicity against human PC9 cells after 72 hrs by MTT assay	[PMID: 30579802]
RAW264.7	IC₅₀	>20 μM Compound: 2	Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced IL-6 production after 48 hrs by ELISA Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced IL-6 production after 48 hrs by ELISA	[PMID: 30579802]
RAW264.7	IC₅₀	>20 μM Compound: 2	Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced TNF-alpha production after 48 hrs by ELISA Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced TNF-alpha production after 48 hrs by ELISA	[PMID: 30579802]
Sf9	IC₅₀	0.6 μM Compound: 1	Inhibition of N-terminal GST-His-tagged c-KIT (544 to 976 amino acids) D816V mutant (unknown origin) expressed in Sf9 insect cells using poly[Glu:Tyr] (4:1) as substrate preincubated for 20 mins followed by [33P-gamma]ATP addition and subsequent inhibitio Inhibition of N-terminal GST-His-tagged c-KIT (544 to 976 amino acids) D816V mutant (unknown origin) expressed in Sf9 insect cells using poly[Glu:Tyr] (4:1) as substrate preincubated for 20 mins followed by [33P-gamma]ATP addition and subsequent inhibitio	[PMID: 26807861]

In Vitro

Pectolinarigenin (5-160 μM; 24 h) reduces the viability of J774A.1 murine macrophages at the concentration of 160 μM, and inhibits LPS (HY-D1056)-induced NO release in J774A.1 murine macrophages^[1].
Pectolinarigenin (1-5 μM; 1 h pre-incubation plus 24 h incubation) inhibits LPS-induced activation of primary mouse cortical astrocytes, suppresses the release of IL-1β and IL-6 in cells, elevates basal IL-10 levels, and restores IL-10 levels reduced by lipopolysaccharide^[1].
Pectolinarigenin (5 μM; 1 h pre-incubation followed by 0.5-1 h incubation) inhibits the activation of NF-κB, ERK1/2 and p38MAPK in lipopolysaccharide-induced primary mouse cortical astrocytes^[1].
Pectolinarigenin (1-50 μM; 24 h, 15 min) inhibits COX-2-mediated PGE₂ production in LPS-stimulated RAW 264.7 cells in a concentration-dependent manner, with an inhibition rate of 99.0% at 50 μM for 24 h, and directly inhibits the enzymatic activity of COX-2 (with an inhibition rate of 44.8% at 50 μM for 15 min)^[2].
Pectolinarigenin (1-50 μM; 10 min pre-incubation + 15 min A23187 (HY-N6687) incubation) dose-dependently inhibits 5-LOX-mediated cysteinyl leukotriene production in A23187-stimulated RBL-1 cells, with an inhibition rate of 97.0% at the concentration of 50 μM (10 min pre-incubation + 15 min A23187 incubation)^[2].
Pectolinarigenin (0.1-10 μM; 24 h) significantly inhibits AAPH (HY-Y0525)-induced Nrf2 pathway-dependent ROS accumulation in HepG2 cells^[3].
Pectolinarigenin (0.1-10 μM; 24 h) induces the expression of antioxidant enzymes in HepG2 cells: it upregulates the expression of heme oxygenase-1, while the 10 μM concentration upregulates the expression of NAD (P) H:quinone oxidoreductase 1 and aldo-keto reductase family 1 member B10^[3].
Pectolinarigenin (0.1-10 μM; 3-24 h) significantly promotes the nuclear accumulation of Nrf2 and enhances ARE-mediated transcriptional activity in HepG2 cells^[3].
Pectolinarigenin (2-8 μM; 12 h pretreatment followed by COM stimulation) concentration-dependently inhibits the COM-induced upregulation of KIM-1 mRNA and protein expression in HK-2 cells, and suppresses cellular inflammatory responses^[4].
Pectolinarigenin (8 μM; 12 h pretreatment followed by COM stimulation) alleviates COM-induced oxidative stress injury in HK-2 cells by restoring the levels of antioxidant markers (GSH, HO-1, GPX4) and reducing the levels of pro-oxidant markers (MDA, iron, ROS)^[4].
Pectolinarigenin (8 μM; 12 h incubation) inhibits HIF-1α activity in HK-2 cells^[4].
Pectolinarigenin (8 μM; 12 h pretreatment followed by COM stimulation) alleviates COM-induced renal injury, inflammation and oxidative stress in HK-2 cells in vitro in a HIF-1α-dependent manner, as its protective effects are abolished when HIF-1α is knocked down^[4].
Pectolinarigenin (25-150 μM; 24 h) dose-dependently inhibits the viability of AGS and MKN28 human gastric cancer cells, with IC₅₀ values of 124.79 μM and 96.88 μM, respectively^[5].
Pectolinarigenin (50-100 μM; 24 h) induces G2/M cell cycle arrest in human gastric cancer cell lines AGS and MKN28, accompanied by sub-G1 phase cell accumulation (indicating apoptosis) in AGS cells. Its mechanism of action involves downregulating the protein expression levels of CDK1 and CDC25C, and upregulating the mRNA expression levels of p53 and p21^[5].
Pectolinarigenin (50-100 μM; 24 h) induces dose-dependent apoptosis in human gastric cancer cell lines AGS and MKN28 by downregulating XIAP and activating the caspase-PARP apoptotic pathway^[5].
Pectolinarigenin (50-100 μM; 24 h) induces Beclin-1-independent autophagy in human gastric cancer cell lines AGS and MKN28^[5].
Pectolinarigenin (50-100 μM; 24 h) dose-dependently inhibits the PI3K/AKT/mTOR signaling pathway in human gastric cancer cell lines AGS and MKN28, thereby reducing the phosphorylation levels of downstream pathway targets p70S6K, 4EBP1 and eIF4E^[5].
Pectolinarigenin (30 μM; 72 h) significantly reduces melanin content and tyrosinase activity in melan-a cells, decreases the protein expression levels of tyrosinase, TRP-1, TRP-2 and MITF, and lowers the mRNA expression levels of tyrosinase, TRP-1 and MITF in the cells^[6].
Pectolinarigenin (30 μM; 2 days) significantly reduces the melanin content in a recombinant human skin model to 20.8% of that in the control group, and decreases the L-DOPA content^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

J774A.1 murine macrophages
Concentration:

5, 10, 20, 40, 80, 160 μM
Incubation Time:

24 h
Result:

Decreased cell viability at 160 μM.
Did not reduce cell viability relative to controls at concentrations below 80 μM.

Immunofluorescence^[1]

Cell Line:

astrocytes primary culture
Concentration:

5 μM
Incubation Time:

1 h pre-incubation plus 24 h incubation
Result:

Restored the structure of damaged filamentous collagen acidic protein (GFAP)

Western Blot Analysis^[3]

Cell Line:

human hepatoma HepG2 cells
Concentration:

0.1, 1.0, 10 μM
Incubation Time:

24 h
Result:

Significantly increased protein expression of heme oxygenase-1 at all tested concentrations.
Significantly increased protein expression of NAD(P)H:quinone oxidoreductase 1 and aldo-keto reductase family 1 member B10 at 10 μM.

Western Blot Analysis^[3]

Cell Line:

human hepatoma HepG2 cells
Concentration:

0.1, 1.0, 10 μM
Incubation Time:

3 h
Result:

Significantly increased nuclear accumulation of Nrf2 at all tested concentrations, with levels normalized to Lamin B.

Cell Viability Assay^[5]

Cell Line:

AGS , MKN28 cells
Concentration:

25, 50, 75, 100, 125, 150 μM
Incubation Time:

24 h
Result:

Inhibited cell growth in a dose-dependent manner in both cell lines.
Reached IC₅₀ values of 124.79 μM for AGS cells and 96.88 μM for MKN28 cells after 24 h of treatment.
Caused massive cell rounding, shrinkage, and detachment from culture plates at 50 and 100 μM after 24 h of treatment.

Cell Cycle Analysis^[5]

Cell Line:

AGS , MKN28 cells
Concentration:

50, 100 μM
Incubation Time:

24 h
Result:

Caused significant accumulation of cells in the G2/M phase in both AGS and MKN28 cells.
Induced a significant increase in sub-G1 phase cells (indicative of apoptotic death) in AGS cells, while inducing a slight increase in sub-G1 phase cells in MKN28 cells.
Downregulated CDK1 and CDC25C protein expression in a dose-dependent manner at 50 and 100 μM.
Increased p53 and p21 mRNA levels in a significant dose-dependent manner in both cell lines, with no significant changes in p53 and p21 protein levels.

Apoptosis Analysis^[5]

Cell Line:

AGS , MKN28 cells
Concentration:

50, 100 μM
Incubation Time:

24 h
Result:

Induced dose-dependent apoptosis in both cell lines.
Increased total apoptotic cells by over 6-fold in AGS cells (with early apoptosis as the major population) and over 5-fold in MKN28 cells (with late apoptosis as the major population) at 100 μM after 24 h.
Showed fragmented or condensed nuclei in treated cells via Hoechst 33342 staining, confirming apoptotic death.
Downregulated XIAP, procaspase-8, procaspase-7, and procaspase-3 in a dose-dependent manner, with concurrent upregulation of cleaved caspase-3, cleaved caspase-7, and cleaved PARP in both cell lines.

Cell Autophagy Assay^[5]

Cell Line:

AGS , MKN28 cells
Concentration:

50, 100 μM
Incubation Time:

24 h
Result:

Induced dose-dependent formation of acidic vesicular organelles (AVOs) in both cell lines.
Increased the LC3-II/LC3-I ratio and p62 expression in a dose-dependent manner, with concurrent dose-dependent downregulation of Beclin-1 expression in both cell lines.

Western Blot Analysis^[6]

Cell Line:

melan-a cells
Concentration:

30 μM
Incubation Time:

72 h
Result:

Reduced protein expression of tyrosinase to 37.9% .
Reduced protein expression of TRP-1 to 42.0% .
Reduced protein expression of TRP-2 to 38.3% .
Reduced protein expression of MITF to 51.5% .

Real Time qPCR^[6]

Cell Line:

melan-a cells
Concentration:

30 μM
Incubation Time:

72 h
Result:

Reduced mRNA expression of tyrosinase to 55.0%.
Reduced mRNA expression of TRP-1 to 10.7 %.
Reduced mRNA expression of MITF to 32.3 %.

In Vivo

Pectolinarigenin (4-100 mg/kg; p.o.; single dose) inhibits arachidonic acid (HY-109590)-induced ear edema in mice when administered orally at 100 mg/kg^[2].
Pectolinarigenin (4-100 mg/kg; p.o.; single dose) produces a 21.1% inhibitory effect on carrageenan-induced paw edema in mice when administered orally at 100 mg/kg^[2].
Pectolinarigenin (20 mg/kg; p.o.; two doses), administered orally at a dose of 20 mg/kg twice, exerts a 30.8% inhibitory effect on passive cutaneous anaphylaxis in rats^[2].
When pectolinarigenin (1.0-10 mg/kg; p.o.; daily; 7 days) is administered orally at a dose of 10 mg/kg once daily for 7 days, it activates the Nrf2/ARE pathway in the liver of male ICR mice, significantly induces the expression of antioxidant enzymes, and promotes Nrf2 nuclear translocation^[3].
Pectolinarigenin (7.25-25 mg/kg; i.g.; daily) alleviates calcium oxalate-induced renal injury, inflammation and oxidative stress in mice in a dose-dependent manner by inhibiting HIF-1α activity^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

ICR (male, 4 weeks old, specific pathogen-free)^[2]
Dosage:

4 mg/kg; 20 mg/kg; 100 mg/kg
Administration:

p.o.; single dose
Result:

Reduced increased ear thickness by 18.7% at 20 mg/kg.
Produced a statistically significant 34.7% inhibition of increased ear thickness at 100 mg/kg.\n
Reduced increased paw volume by 2.6% at 4 mg/kg.
Reduced increased paw volume by 13.2% at 20 mg/kg.
Reduced increased paw volume by 21.1% at 100 mg/kg.

Animal Model:

Sprague-Dawley (male, 4 weeks old, specific pathogen-free)^[2]
Dosage:

20 mg/kg
Administration:

p.o.; two doses (1 hour before IgE injection and 1 hour before antigen challenge)
Result:

Produced a 30.8% inhibition of the allergic response.

Animal Model:

ICR mice (male, 6-week-old)^[3]
Dosage:

1.0 mg/kg; 10 mg/kg
Administration:

p.o.; daily; 7 days
Result:

Significantly increased liver protein expression of heme oxygenase-1 (HO-1) and aldo-keto reductase family 1 member B10 (AKR1B10), and significantly promoted nuclear translocation of nuclear factor-erythroid-2-related factor 2 (Nrf2) in the liver at 10 mg/kg.
Did not produce statistically significant increases in HO-1, AKR1B10 expression, or Nrf2 nuclear translocation at 1.0 mg/kg.
Reached plasma concentrations of 0.92 μM (1.0 mg/kg group) and 1.09 μM (10 mg/kg group) 2 hours after the final dose.

Animal Model:

C57BL/6J mice (male, 6-8 weeks old, 22-24 g)^[4]
Dosage:

7.25 mg/kg; 12.5 mg/kg; 25 mg/kg
Administration:

i.g.; daily
Result:

Reduced serum creatinine and blood urea nitrogen (BUN) levels in a concentration-dependent manner.
Attenuated renal tubular damage (assessed via PAS staining) and reduced renal calcium oxalate crystal deposition in a concentration-dependent manner.
Inhibited the glyoxylate-induced increase in KIM-1 protein and mRNA expression.
Impeded the glyoxylate-induced elevation of inflammatory factors (IL-6, MCP-1, TNF-α) at the mRNA level, and inhibited phosphorylation of P65.
Reduced renal malondialdehyde (MDA) and iron levels, and increased reduced glutathione (GSH) levels, in a concentration-dependent manner.
Upregulated renal expression of HO-1 and GPX4 proteins.
Inhibited the activity of HIF-1α (assessed via luciferase reporter assay) without reducing HIF-1α protein or mRNA expression.

Chemical Information

CAS. Nr. 520-12-7
Appearance Solid
Molecular Weight 314.29
Formel C₁₇H₁₄O₆
Color Light yellow to yellow
SMILES

O=C1C=C(C2=CC=C(OC)C=C2)OC3=CC(O)=C(OC)C(O)=C13
Structure Classification
- Flavonoids
- Flavones
- Phenols
- Polyphenols
Initial Source
- Plants
- Compositae
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (2)

All Histological Imaging/StainingIFWBCell Proliferation/Viability AssayApoptosis Analysis

Sort by:

Journal Impact Factor

Autophagy

XIAP-ULK1-Mediated mitophagy modulates carnitine metabolism to mitigate diabetic kidney disease. [Abstract]

2025 Oct 25. PMID: 41139215
Chem Biol Interact

Pectolinarigenin attenuates hepatic ischemia/reperfusion injury via activation of the PI3K/AKT/Nrf2 signaling pathway. [Abstract]

2023 Dec 1:386:110763. PMID: 37832626

Pectolinarigenin purchased from MedChemExpress. Usage Cited in: Chem Biol Interact. 2023 Dec 1:386:110763. [Abstract]

H&E staining and quantification of necrotic area of liver tissue treated with Pectolinarigenin (Pec) (10 mg/kg, i.p.).

Pectolinarigenin purchased from MedChemExpress. Usage Cited in: Chem Biol Interact. 2023 Dec 1:386:110763. [Abstract]

DHE stained sections of fluorescence intensity of liver tissue treated with Pectolinarigenin (Pec) (10 mg/kg, i.p.).

Pectolinarigenin purchased from MedChemExpress. Usage Cited in: Chem Biol Interact. 2023 Dec 1:386:110763. [Abstract]

Protein levels and relative quantification analysis of Bax, Bcl-2, Bcl-xl, and cleaved caspase-3 in liver tissue treated with Pectolinarigenin (Pec) (10 mg/kg, i.p.).

Pectolinarigenin purchased from MedChemExpress. Usage Cited in: Chem Biol Interact. 2023 Dec 1:386:110763. [Abstract]

Cell viability after receiving discrepant Pectolinarigenin (Pec) (0, 2.5, 5. 10, 20, 40 μM) concentrations.

Pectolinarigenin purchased from MedChemExpress. Usage Cited in: Chem Biol Interact. 2023 Dec 1:386:110763. [Abstract]

Flow cytometry detection of apoptosis treated with Pectolinarigenin (Pec) (10 μM).

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 33.33 mg/mL (106.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.1818 mL

15.9089 mL

31.8177 mL

5 mM

0.6364 mL

3.1818 mL

6.3635 mL

10 mM

0.3182 mL

1.5909 mL

3.1818 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 2% DMSO 98% (20% SBE-β-CD in Saline)

Solubility: ≥ 1 mg/mL (3.18 mM); Clear solution

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 1 mg/mL (3.18 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (310 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Heimfarth L, et al. Neuroprotective and anti-inflammatory effect of pectolinarigenin, a flavonoid from Amazonian Aegiphila integrifolia (Jacq.), against lipopolysaccharide-induced inflammation in astrocytes via NFκB and MAPK pathways. Food Chem Toxicol. 2021;157:112538. [Content Brief]

[2]. Lim H, et al. Anti-inflammatory activity of pectolinarigenin and pectolinarin isolated from Cirsium chanroenicum. Biol Pharm Bull. 2008;31(11):2063-2067. [Content Brief]

[3]. Shiraiwa M, et al. Pectolinarigenin Induces Antioxidant Enzymes through Nrf2/ARE Pathway in HepG2 Cells. Antioxidants (Basel). 2022;11(4):675. Published 2022 Mar 30. [Content Brief]

[4]. Yao R, et al. Pectolinarigenin alleviates calcium oxalate-induced renal inflammation and oxidative stress by binding to HIF-1α. Int Immunopharmacol. 2024;143(Pt 1):113284. [Content Brief]

[5]. Lee HJ, et al. Pectolinarigenin Induced Cell Cycle Arrest, Autophagy, and Apoptosis in Gastric Cancer Cell via PI3K/AKT/mTOR Signaling Pathway. Nutrients. 2018;10(8):1043. Published 2018 Aug 8. [Content Brief]

[6]. Lee S, et al. Pectolinarigenin, an aglycone of pectolinarin, has more potent inhibitory activities on melanogenesis than pectolinarin. Biochem Biophys Res Commun. 2017;493(1):765-772. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.1818 mL	15.9089 mL	31.8177 mL	79.5444 mL
	5 mM	0.6364 mL	3.1818 mL	6.3635 mL	15.9089 mL
	10 mM	0.3182 mL	1.5909 mL	3.1818 mL	7.9544 mL
	15 mM	0.2121 mL	1.0606 mL	2.1212 mL	5.3030 mL
	20 mM	0.1591 mL	0.7954 mL	1.5909 mL	3.9772 mL
	25 mM	0.1273 mL	0.6364 mL	1.2727 mL	3.1818 mL
	30 mM	0.1061 mL	0.5303 mL	1.0606 mL	2.6515 mL
	40 mM	0.0795 mL	0.3977 mL	0.7954 mL	1.9886 mL
	50 mM	0.0636 mL	0.3182 mL	0.6364 mL	1.5909 mL
	60 mM	0.0530 mL	0.2651 mL	0.5303 mL	1.3257 mL
	80 mM	0.0398 mL	0.1989 mL	0.3977 mL	0.9943 mL
	100 mM	0.0318 mL	0.1591 mL	0.3182 mL	0.7954 mL

Pectolinarigenin

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Pectolinarigenin

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Phenols Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Flavonoids Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library